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Tumour progression is associated with the accumulation of genetic
changes which can result in eventual acquisition of malignant
properties, i.e. in the emergence of tumour cell populations that
have acquired a sufficient number of properties to allow them to
metastasize. In this regard, proteolytic degradation of the extracel-
lular matrix is thought to play a crucial role in the liberation and
seeding of cancer cells during the process of metastasis (Stetler-
Stevenson et al, 1996). Furthermore, the family of matrix metallo-
proteinases (MMP) is likely to be responsible for much of the
proteolytic degradation associated with tumour cell invasion. This
is because members of this family have a wide substrate speci-
ficity, including type IV or basement membrane collagen, and are
often associated with normal and disease processes in which
turnover of matrix components is essential to the process
(MacDougall and Matrisian, 1995). A role for the MMPs in metas-
tasis is also supported by the fact that transfection of metastatic
cancer cell populations with the gene that encodes the endogenous
inhibitor of MMPs, tissue inhibitor of metalloproteinase (TIMP-
1), markedly inhibits both experimental and spontaneous metas-
tasis in a number of models (DeClerck et al, 1992). This regulatory
role of TIMPs suggests that it is the net proteolytic balance
between the production of enzymes and their inhibitors that deter-
mines the metastatic capacity of the cells (DeClerck and Imren,
1994).
The MMP subfamily of the gelatinases, in particular, has been a
focus of study since these enzymes have been shown to have the
ability to degrade type IV collagen (Collier et al, 1988; Wilhelm et
al, 1989), a property thought to be required by all cells crossing any
basement membrane. Gelatinase B has been demonstrated, by
transfection analysis, to confer metastatic competence upon non-
metastatic rat fibroblastic cells, thus implicating it as a possible key
enzyme in the process of metastasis (Bernhard et al, 1994). The
demonstration that gelatinase B is involved in tissue invasion of
normal trophoblasts (Librach et al, 1991) and macrophages
(Watanabe et al, 1993) also lends support to its role as an enzyme
mediating invasiveness of both normal and malignant cells. Despite
this information, however, little is known about the regulation of
gelatinase B expression, and how it can become de-regulated
during cancer progression. Studies have shown the gene which
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Summary Although it is generally accepted that proteolytic degradation is an important mechanism used by malignant cells in the process of
metastasis, comparatively little is known about the regulation of molecules responsible for proteolysis and how they become de-regulated
during human tumour progression. Using a genetically related pair of human melanoma cell lines, derived from the same patient at different
stages of disease, we analysed differences in the cytokine-mediated regulation of gelatinase B (MMP-9), an enzyme thought to play an
important role in cellular invasiveness, and TIMP-1, a physiological inhibitor of this enzyme. Whereas the advanced stage (i.e. metastatic)
partner of this pair (WM 239) could produce gelatinase B upon induction with interleukin (IL)-1b or tumour necrosis factor alpha (TNF-a), the
early stage (i.e. primary) partner (WM 115) could not. In sharp contrast, we found that TIMP-1 displayed an opposite pattern of induction in
these cell lines. Specifically, the early stage cell line, WM 115, demonstrated a marked increase in the production of TIMP-1 when treated with
IL-1b or TNF-a whereas the advanced cell line, WM 239, showed no such increase. Treatment with the DNA demethylating agent, 2-deoxy-
5-azacytidine, resulted in a marked up-regulation of both gelatinase B and TIMP-1 in both cell lines. It was further found that constitutive
overexpression of gelatinase B in WM 239 cells and an additional melanoma cell line (MeWo), derived from a metastatic lesion, was able to
greatly enhance lung colonization in an experimental metastasis assay while we did not observe differences in tumorigenicity. From these
results we conclude that an altered responsiveness of gelatinase B and TIMP-1 to induction by similar agents is associated with disease
progression in human melanoma and that this altered responsiveness can have consequences to the aggressive nature of the disease.
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24100, Italyencodes gelatinase B is positively controlled by inflammatory
cytokines such as tumour necrosis factor (TNF)-a and interleukin
(IL)-1b (Sato and Seiki, 1993; Unemori et al, 1991), growth factors
such as transforming growth factor (TGF)-b (Salo et al, 1991) and
other agents such as TPA (Moll et al, 1990). Gelatinase B expres-
sion has also been shown to be negatively controlled by the adeno-
virus E1A protein (Frisch et al, 1990) and as a consequence of
somatic fusion in melanoma cells (MacDougall et al, 1995).
Regulation of MMPs by cytokines and other agents is only one of
the ways in which the net proteolytic balance of tumour cells can be
tipped in favour of matrix degradation. Thus, the inhibitors of MMPs
are also thought to contribute an important role in determining the
extracellular activity of secreted MMPs. The TIMP family, which
consists of four members, TIMP-1, -2, -3 and -4, are thought to func-
tion by binding to the active site of matrix metalloproteinases, and
hence inhibiting their function. Like the MMPs, the TIMPs also have
been found to be regulated by a number of different cytokines and
growth factors. Perhaps most significantly, TGF-b has been demon-
strated to play a pivotal role in the regulation of wound healing
(Mustoe et al, 1987), possibly by induction of cellular TIMP produc-
tion (Edwards et al, 1987). Inflammatory mediators such as IL-1b
and TNF-a have also been shown to regulate the levels of TIMPs
produced by various cell types (Ito et al, 1990).
We have previously demonstrated that melanoma cells may
undergo a ‘switch’ in permissivity of gelatinase B expression, that
is, advanced melanoma cells are able to express gelatinase B either
constitutively or through induction with cytokines while early stage
melanoma cells do not express this molecule under any conditions
(MacDougall et al, 1995). Using a genetically related pair of human
melanoma cell lines, one derived from a primary melanoma, the
other derived from a lymph node metastasis isolated 16 months
later from the same patient (Kath et al, 1991), we have addressed
the hypothesis that melanoma cells may undergo a ‘proteolytic
switch’ during disease progression. As a consequence of this
switch, we show that the more aggressive cells not only acquire the
ability to produce gelatinase B in response to cytokine treatment
but also lose the ability to produce an inhibitor of gelatinase B,
specifically TIMP-1, after identical treatment. In contrast, the less
aggressive cells are unable to produce gelatinase B under cytokine
treatment, but maintain a robust TIMP-1 induction under similar
circumstances. In addition, we describe a heretofore unreported
effect of the DNA demethylating agent 2-deoxy-5-azacytidine on
the production of gelatinase B and TIMP-1. We finally present
evidence for a functional consequence of this ‘proteolytic switch’
by demonstrating a marked increase in lung colonization by
melanoma cells engineered to constitutively express gelatinase B.
MATERIALS AND METHODS
Cell culture, collection of conditioned media and
growth factors
Melanoma cell lines, kindly provided by Dr M Herlyn (Wistar
Institute, Philadelphia, PA, USA) were routinely grown in RPMI-
1640 (Gibco) media supplemented with 5% fetal bovine serum
(FBS; Hyclone) in a humidified atmosphere containing 5% carbon
dioxide at a constant temperature of 378C. The cell lines were
derived from the same patient in a sequential manner. WM 115
was derived from a vertical growth phase (VGP) primary lesion
whereas WM 239 was derived from a lymph node metastasis 16
months later (Kath et al, 1991).
Conditioned media from the cell lines was collected as follows.
Melanoma cells were plated at a density of 3.0 3 105 per well of a
6-well plate (Nunc) and incubated overnight in ExCell 300 media
(JR Scientific) supplemented with 2% FBS. Cells were then
washed with serum-free ExCell 300, incubated for 4 h and washed
again with fresh serum-free ExCell 300 with or without TNF-a or
IL-1b (UBI, Lake Placid, NY, USA) at a concentration of
5.0 ng ml21. Treatment with 2-deoxy-5-azacytidine followed a
slightly different protocol. Cells were treated with 4.5 mM 2-
deoxy-5-azacytidine for 48 h in serum containing medium prior to
plating at a density of 3.0 3 105 per well of a 6-well plate and
subsequent washes with serum-free medium as described above.
In either case, after 48 h serum-free conditioned medium was
centrifuged to remove cellular debris, aliquoted and either used
immediately, or frozen at 2 708C.
Quantitation of protein in melanoma cell conditioned
medium
The concentration of protein secreted by melanoma cells into
serum-free media was assayed by the method described by
Bradford (1976). Briefly, 50 ml of serum-free conditioned media
were aliquoted into the wells of a 96-well enzyme-linked
immunosorbent assay (ELISA) plate and mixed 1:4 with a solution
of 0.01% Coomassie brilliant blue G-250 (Merck) in 4.7% ethanol
and 8.5% phosphoric acid (Sigma). After 5–10 min of incubation
at ambient temperature, the absorbance of the samples were
measured at 595 nm and corrected against 410 nm. Concentration
of protein was calculated by substitution of values into a least
squares fitted standard curve of bovine serum albumin (BSA;
Pierce) between 0.5 and 10 mg ml21. All samples and standards
were performed in quadruplicate and all sample points fell within
the range of the standard curve.
Substrate-embedded gel electrophoresis
Substrate-embedded gel electrophoresis, or zymography, was
performed essentially as reported (Herron et al, 1986). Briefly,
sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) gels were prepared at a concentration of 10%
containing 1.0 mg ml21 of gelatin (Sigma). The resolving gel was
overlaid with a stacking gel of 5% acrylamide not containing
gelatin. A volume of conditioned media equivalent to 200 ng of
protein was mixed with SDS sample buffer without reducing agent
or boiling and subsequently electrophoresed at a constant current
of 20 mA per gel. Upon completion of electrophoresis the gels
were washed twice for 15 min in 2.5% Triton X-100 (Sigma),
rinsed briefly with water and then incubated overnight at 378C in a
solution of 50 mM Tris–HCl (Sigma), pH 7.0, 5 mM calcium chlo-
ride (Sigma) and 0.02% NaN3 (Sigma). After incubation, the gels
were stained in a solution of 0.1% Coomassie brilliant blue R-250
in 40% methanol and 20% acetic acid and destained in the same
solution without Coomassie brilliant blue R-250. The resulting
gels showed areas of clearing where the substrate within the gel
has been digested away.
Reverse transcription-polymerase chain reaction
analysis
Messenger RNA for gelatinase B was assayed by reverse tran-
scription-polymerase chain reaction analysis (RT-PCR) briefly as
follows. RNA from control or treated cells was isolated by cell
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lysis in 4.0 M guanidine isothiocyanate and subsequent phenol–
chloroform extraction as previously described (Chomczynski and
Sacchi, 1987). One mg of total RNA was reverse transcribed in a
20 ml reaction containing 200 units of Mu-MLV reverse transcrip-
tase (Gibco), 1.0 mM each dNTP, 50 mM Tris–HCl pH 8.3, 75 mM
potassium chloride (KCl), 10 mM dithiotreitol (DTT), 3.0 mM
magnesium chloride (MgCl2) and 0.1 mg oligo-dT12. The products
of reverse transcription were then subjected to 35 cycles of PCR in
10 mM Tris–HCl pH 9.0, 50 mM KCl, 1.5 mM MgCl2, 0.5 units Taq
polymerase (Pharmacia) and 50 pMol of each upstream and down-
stream primer. The cycle parameters were: 5 cycles of 5 min at
958C, 3 min at 588C and 5 min at 728C, the remaining 30 cycles
being performed for 1.5 min at each temperature. Primers used
were those described by Onisto and colleagues (Onisto et al, 1994)
which have been described to be specific for gelatinase B.
Reaction products were analysed by electrophoresis through a 2%
agarose gel and visualized by ethidium bromide staining and UV
transillumination.
Northern blot analysis
Total RNA was isolated from cells as described for RT-PCR.
Twenty micrograms of total cellular RNA were electrophoresed
through a 1.0% agarose gel containing 6.0% formaldehyde and 13
MOPS buffer (40 mM 4-morpholinepropanesulphonic acid, 10 mM
sodium acetate and 1.0 mM EDTA, pH 7.0). After electrophoresis,
the separated RNAs were capillary transferred to hybond-N blot-
ting membrane (Amersham) overnight in 10 3 saline–sodium
citrate (SSC). The immobilized RNAs were prehybridized at 688C
in a solution of 6 3 SSC (1 3 SSC is 150 mM sodium chloride
(NaCl), 15 mM sodium citrate, pH 7.0), 2 3 Denhardt’s solution (1
3 Denhardt’s solution is 0.02% Ficoll (type 400), 0.02%
polyvinylpyrrolidone, 0.02% BSA) and 0.5% SDS and hybridized
in the same solution at 688C with a fragment of the TIMP-1 cDNA
radioactively labelled by the random priming method (Pharmacia;
Quickprime kit). Hybridization was carried out overnight with
agitation. After hybridization, the filter was washed twice in
2 3 SSC/0.1% SDS for 15 min at 688C and then twice in
0.1  3 SSC/0.1% SDS at 688C. The washed filter was subjected to
autoradiography at 2 708C.
Preparation of cell lysates and Western blot analysis
In the preparation of lysates, monolayers of cells were washed 3
times with cold PBS and then lysed on ice in situ in 500 ml of
modified RIPA lysis buffer (1% Triton X-100 (BDH), 0.1% SDS
(BDH), 50 mM Tris–HCl pH 7.5, 150 mM NaCl, 5.0 mM EDTA).
After 15 min lysates were collected, centrifuged to remove debris
and assayed for protein concentration by the method of Bradford
(1976), as previously described. For partial purification of gelati-
nases, 500 mg of protein was incubated with 25 ml of gelatin
immobilized on agarose beads (Sigma; 3–6 mg ml21) at 48C for
2–4 h after which the beads were washed once with modified
RIPA buffer and then once with PBS. Proteins bound to the gelatin
were eluted with SDS-PAGE sample buffer and analysed by
Western blot analysis.
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Figure 1 Growth of WM 115 and WM 239 in vivo. One million WM 115 (l)
or WM 239 (n) cells in 50 ml were injected subdermally into the flank of 6- to
8-week-old female nude mice. At the appearance of tumour growth,
measurements and calculations were made as described in Materials and
Methods. The data are representative and are presented as the mean 6 s.d.
of four animals for both WM 115 and WM 239
Figure 2 Gelatin zymography and Western blot analysis of conditioned
media and lysates from melanoma cell lines for the expression of gelatinase
B and TIMP-1. WM 115 and WM 239 cells either untreated (control) or
treated with 5.0 ng ml21 of IL-1b, 5.0 ng ml21 TNF-a or 4.5 mM 2-deoxy-5-
azacytidine (5-aza-c). (A) Gelatin zymography of conditioned media from
cells treated under the above conditions. The arrows indicate the migration of
gelatinase A and B. Note no change in gelatinase A under all conditions.
(B) A Western blot analysis of concentrated conditioned media (10 mg of
protein) from cells treated under the above conditions. The arrow indicates
the migration of gelatinase B. Note the similar pattern of production as seen
with gelatin zymography. (C) Gelatinase B Western blot analysis of partially
purified lysates from cells treated under the conditions described. (D) TIMP-1
Western blot analysis of 10 mg of protein from WM 115 and WM 239 cells
treated under the conditions describedGelatinase B and TIMP-1 induction in melanoma progression 507
British Journal of Cancer (1999) 80(3/4), 504–512 © Cancer Research Campaign 1999
Western blot analysis was carried out using standard techniques.
Briefly, conditioned medium (10 mg of protein) that had been
concentrated by ultrafiltration (Amicon microcentrifuge concentra-
tors; 10 000 MW cut-off) or partially purified cell lysate was elec-
trophoresed through a 10% SDS-polyacrylamide gel and
electro-transferred to polyvinylidene difluoride (PVDF) blotting
membrane (Immobilon-P, Millipore) overnight at 48C in transfer
buffer (50 mM Tris, 380 mM glycine, 0.1% SDS, 20% methanol) at
a constant voltage of 15 V. The membrane was subsequently
blocked in a solution of 5% skim milk powder in PBS/0.1% Tween-
20 (PBS-T) for 1 h at ambient temperature. The membrane was
probed with a murine monoclonal antibody against gelatinase B
(GE 213c, a gift of Oncologix Inc., 1:1000 dilution) or affinity-
purified rabbit polyclonal anti-TIMP-1 antibody (Triple Point
Biologicals; 1:2500 dilution) for 2 h at ambient temperature and
washed twice for 15 min each in PBS-T. The membrane was then
probed with an anti-mouse or anti-rabbit horseradish peroxidase-
conjugated secondary antibody for 45 min (Bio-rad, 1:5000) and
similarly washed twice for 15 min each. The membrane was
subsequently processed for enhanced chemiluminescence detection
(ECL, Amersham) according to the manufacturer’s instructions.
Transfection and overexpression of gelatinase B cDNA
Transfection of melanoma cells either with the plasmid constructs
pRc/RSV or pRc/RSV–MMP-9 were performed using Lipofectin
reagent (Gibco) according to manufacturer’s instructions. Briefly,
0.5–2.5 3 106 cells were plated in growth media and allowed to
attach overnight. The following day, 5–10 mg of purified plasmid
DNA in 100 ml were mixed with an equal volume of a 1:5 dilution
of lipofectin reagent and incubated at room temperature for
10 min. During this time, the monolayers of melanoma cells were
washed twice with serum-free Ex-Cell 300 media. The DNA–lipo-
fectin mixture was then diluted to a final volume of 2.0 ml and
added to the cell monolayers. The cells were subsequently incu-
bated at 378C, 5% carbon dioxide overnight. Following this incu-
bation the cell monolayers were washed once, re-fed with growth
medium and incubated an additional 24 h prior to selection in
media containing 800 mg ml21 of G418 (Gibco). After drug selec-
tion was complete, approximately 2 weeks, drug-resistant colonies
were pooled and used for subsequent analysis.
Assay for tumorigenicity in nu/nu mice
Cell lines were harvested, washed once with serum containing
medium and then twice with serum-free, calcium and magnesium-
free HBSS and adjusted to the appropriate concentration. Fifty
microlitres of cell suspension (1.0 3 106 cells for WM 239 and
WM 115); 2.0 3 105 for WM 239/WM 239.92 or MeWo/
MeWo.92) was injected subdermally into the sides of each of four
(WM 115 and WM 239) or five (WM 239/WM 239.92 or
MeWo/MeWo.92) 6- to 8-week-old female nu/nu mice (Cornil
et al, 1989). Tumour growth was monitored using calipers to
measure two dimensions of the tumour and then applying the
following formula to approximate tumour volume: volume
(cm3) 5 width2 3 (length/2).
Assay for experimental metastasis formation
The same single cell suspension described for the assay of tumori-
genicity was adjusted such that 200 ml of cell suspension (2.0 3 106
cells, WM 239; 1.0 3 106, MeWo) was injected intravenously (i.v.)
into the lateral tail vein of 6 to 8-week-old female nu/nu mice.
Animals were sacrificed at 10 weeks after injection of MeWo or
MeWo.92 cells, or at 12 weeks after injection of WM 239 or WM
239.92 cells. At the time of sacrifice, animals were autopsied,
examined for gross pathology and the lungs were fixed in Bouins
fixative (BDH Chemical). The lungs were enumerated with the aid
of a dissecting microscope for gross cellular colonization.
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Figure 3 Gelatinase B RT-PCR analysis of RNA isolated from melanoma
cell lines. WM 115 and WM 239 cells either untreated (control) or treated with
5.0 ng ml21 of IL-1b, 5.0 ng ml21 TNF-a or 4.5 mM 2-deoxy-5-azacytidine
(5-aza-c). The lane labelled MW marker is the 123 bp ladder (Gibco) and the
lane labelled (–) control corresponds to the reaction in which RNA was left out
of the experiment. The arrow indicates the migration of the predicted 640 bp
PCR product which is indicative of the presence of gelatinase B mRNA
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Figure 4 TIMP-1 Northern blot analysis of RNA isolated from melanoma
cell lines. WM 115 cells or WM 239 cells either untreated (control) or treated
with 5.0 ng ml21 of IL-1b, 5.0 ng ml21 TNF-a or 4.5 mM 2-deoxy-5-azacytidine
(5-aza-c). GAPDH hybridization is included as a control for difference in
sample loading508 JR MacDougall et al
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RESULTS
Genetically related melanoma cell lines differ in their
in vivo behaviour
Figure 1 depicts the resulting growth curves of WM 115 (primary
melanoma) and WM 239 (metastasis) after subdermal injection of
1.0 3 106 cells. It is evident that the WM 239 tumours grow at an
enhanced rate when compared to WM 115 tumours. In fact, WM
115 cells require about twice as much time (26 days) to grow to the
same size (0.1 cm3) as WM 239 tumours (13 days). In addition,
while the WM 239 cells are able to colonize the lungs of nu/nu
mice after i.v. injection, WM 115 cells are unable to do so (data not
shown). Taken together, these data reflect the difference in aggres-
siveness of these cells and provide evidence that these two cell
lines exhibit characteristics in nude mice consistent with the
clinical stage at derivation.
WM 115 and WM 239 differ in their induced expression
of gelatinase B
Figure 2 shows the results of several experiments designed to
examine the production of gelatinase B in WM 115 (primary
melanoma) and WM 239 cells (metastasis) in response to IL-1b,
TNF-a and 2-deoxy-5-azacytidine. Panel A shows, by gelatin
zymography, that WM 115 cells were unable to produce gelatinase
B under conditions of no treatment or with IL-1b or TNF-a
stimulation. Treatment of these cells with 2-deoxy-5-azacytidine
revealed some stimulation of gelatinase B production. In contrast
to this, WM 239 cells were able to respond to all treatments by a
marked induction of gelatinase B production. In addition, treat-
ment of WM 239 with either TNF-a or 2-deoxy-5-azacytidine also
induced the production of ‘activated’ gelatinase B as demonstrated
by the presence of a band migrating slightly faster that the parent
molecule. Of interest was the observation that the levels of the
72 kDa gelatinase A appeared to be unaffected by treatment with
any of the agents used in these experiments. The results obtained
using gelatin zymography were confirmed when the same condi-
tioned media, or partially purified lysates from the same cells,
were examined by Western blotting analysis. Figure 2B shows
identical results to those found with zymographic analysis in that
the enzyme protein levels in conditioned media change with
cytokine or 2-deoxy-5-azacytidine treatment and similarly, as
shown in Figure 2C, the same pattern of protein expression from
partially purified cell lysates. Furthermore, there is also a quantita-
tive difference in the effect that 2-deoxy-5-azacytidine has on the
induction of gelatinase B in WM 115 cells when compared to WM
239 cells. Thus, it appears that in this genetically related pair of
cell lines, there is a distinct difference in the ability of the cell lines
to produce gelatinase B in response to the inflammatory cytokines
IL-1b and TNF-a, and the DNA demethylating agent 2-deoxy-5-
azacytidine, which occurs as a function of disease progression.
TIMP-1 expression shows an opposite pattern to that of
gelatinase B in WM 115 and WM 239 cells
It is known that an important inhibitor of gelatinase B, namely
TIMP-1, is also modulated by the inflammatory cytokines IL-1b
and TNF-a (Ito et al, 1990). With this in mind, we examined the
expression of the TIMP-1 gene in this genetically related pair of
cell lines in response to treatment with IL-1b, TNF-a and 2-
deoxy-5-azacytidine. Figure 2D depicts Western blot analysis and
demonstrates that, in contrast to the induction of gelatinase B, it is
the early stage melanoma cell line, WM 115, that is responsive
to cytokine and 2-deoxy-5-azacytidine treatment, whereas the
advanced stage cell line WM 239, is refractory to similar cytokine
treatment. As is evident from the Figure, WM 115 shows a strong
induction of TIMP-1 protein levels in response to IL-1b, TNF-a
and 2-deoxy-5-azacytidine while WM 239 is induced to produce
TIMP-1 only with 2-deoxy-5-azacytidine treatment but is not
affected by IL-1b or TNF-a treatment. Thus, it appears that while
WM 115 cells respond to IL1b or TNF-a treatment by a robust up-
regulation of TIMP-1 production, WM 239 cells are unable to
elicit such a response.
Cytokine- and 2-deoxy-5-azacytidine-mediated
regulation of gelatinase B and TIMP-1 occurs at the
level of steady-state mRNA
We next tried to assess at what level this phenomenon was being
regulated. As shown in Figure 3, the predicted 640 bp PCR
product for gelatinase B, which is present in the lanes corre-
sponding to RNA isolated from IL-1b- and TNF-a-treated WM
239 cells, is absent from the lanes corresponding to RNA isolated
from similarly treated WM 115 cells. The lanes corresponding to
2-deoxy-5-azacytidine-treated WM 115 and WM 239 cells show
the predicted 640 bp PCR product implying that treatment of these
cells with this agent induces the transcription of gelatinase B gene
in both cell lines. This assay was repeated several times on
different RNA preparations and, in all cases, glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was also amplified in
separate reactions to ensure the integrity of the cDNA synthesis
reaction (data not shown). These experiments demonstrate that the
regulation of gelatinase B by IL-1b, TNF-a and 2-deoxy-5-azacy-
tidine in these cells is most likely at the level of mRNA transcrip-
tion and that the difference in the production of this molecule
between these two cell lines seems to be at the level of induction of
gelatinase B mRNA.
It was further determined (Figure 4) that the induction of TIMP-
1 in the early-stage cell line WM 115 was at the level of the steady-
state mRNA. Northern blot analysis of the same RNAs used for
RT-PCR analysis depicted in Figure 3 show that, while RNAs
derived from WM 115 cells show a strong induction for TIMP-1,
the RNAs derived from WM 239 cells show no such induction.
Thus the TIMP-1 results are a virtual mirror image of the pattern
seen for gelatinase B and suggest that these two molecules may
be coordinately de-regulated during the progression of human
melanoma.
Figure 5 Gelatin zymogram of conditioned medium derived from
transfected melanoma cells. WM 239 or MeWo cells were transfected with
either control or gelatinase B containing cDNA expression vectors as
described in Materials and Methods. Note presence of gelatinase B activity in
the cells transfected with expression vector containing gelatinase B cDNA
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Constitutive expression of gelatinase B in melanoma
cells leads to an enhancement of lung colonization
in vivo
Given the results so far, it was evident that there was a distinct
difference in the ability of each of these cells lines to produce
gelatinase B and TIMP-1 following induction with cytokines. It
was also clear that, while gelatinase B was not constitutively
produced by either cell line, TIMP-1 was. This prompted us to
consider the effect of constitutive overexpression of gelatinase B
in WM 239 cells and another melanoma cell line, MeWo, to deter-
mine the ability of these cells to colonize the lungs of nu/nu mice
in an experimental metastasis assay. We surmised that if we ‘tip’
the proteolytic balance toward gelatinase B production over
constitutive TIMP-1, there might be an enhanced tendency of the
gelatinase B overexpressing cells to have an altered behaviour in
vivo. Figure 5 demonstrates that cells transfected with an expres-
sion vector carrying gelatinase B cDNA overexpress this enzyme
at the protein level using gelatin zymography whereas vector-
transfected control cells remain gelatinase B-negative. Having
derived gelatinase B overexpressing cells, we then sought to assess
aspects of their phenotypic behaviour in vivo.
Figure 6 summarizes the results of tumor growth measurements
of WM 239 or MeWo cells transfected with either control or
gelatinase B cDNA containing vectors. For both WM 239 and
WM 239.92 cells, the time for the tumours to attain a size of 0.5
cm3 (approximately 0.5 g) was roughly 6 weeks with no difference
in tumour take (100% for both cell lines), tumour doubling time or
tumour onset. The same result was true for MeWo and MeWo.92
cells. In this case, both cell lines took about 7 weeks to reach 0.5
cm3 but, similarly, showed no difference in tumour take (100% for
both cell lines), tumour doubling time and no difference in tumour
onset.
When WM 239, WM 239.92, MeWo and MeWo.92 cells were
assessed for their ability to colonize the lungs of nu/nu mice in an
experimental metastasis assay (Figure 7), it was found that the
cells overexpressing gelatinase B had an enhanced ability to do so.
WM 239.92 cells were found to colonize the lungs in six of seven
mice injected with the median number of nodules per lung being
17 (range 0–200). The control-transfected WM 239 cells were
found to colonize the lungs of only five of seven mice injected
with a median number of nodules per lung being 4 (range 0–14).
Two animals in the WM 239.92 group had to be sacrificed at 9
weeks due to signs of morbidity. One of these animals showed
extensive tumour cell infiltration into the chest wall while the
other showed signs of lower limb paralysis. A third animal, at the
completion of the experiment (12 weeks), also had evidence of
extensive tumour cell infiltration into the chest wall as well as a
metastasis to the knee joint in a lower limb. MeWo cells over-
expressing gelatinase B also showed a similar increase in the
ability to colonize the lungs of nu/nu mice when compared to
vector-transfected controls. MeWo.92 cells were found to colonize
the lungs in five of five mice injected giving rise to a median
nodule number of 84 (range 38– . 200) while control-transfected
cells colonized the lungs of only four of five mice injected giving
a median nodule number of 42 (range 0–55). In either case, the
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Figure 6 Growth of control and gelatinase B-transfected melanoma cells in
vivo. Two hundred thousand WM 239 (top panel) or MeWo (bottom panel)
cells either transfected with control (n) or gelatinase B cDNA (l l •) containing
plasmid suspended in 50 ml were injected subdermally into the flank of 6- to
8-week-old female nude mice. At the appearance of tumour growth,
measurements and calculations were made as described in Materials and
Methods. The data are presented as the mean 6 s.d. of five animals for all
groups
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Figure 7 Experimental metastasis assays. WM 239 (l l) and WM 239.92
(l) cells (2.0 3 106) or MeWo (n n) and MeWo.92 (n) cells (1.0 3 106) were
injected into the tail vein of 6- to 8-week-old nu/nu mice. Mice were sacrificed
10 weeks after injection of MeWo and MeWo.92 cells or 12 weeks after
injection of WM 239 and WM 239.92 cells. The results are expressed as the
number of nodules for each lung examined (n 5 7 for WM 239 and WM
239.92; n 5 5 for MeWo and MeWo.92). The bars represent the median for
each group. * represents statistical significance (P , 0.05) based on a non-
parametric Mann–Whitney U-test510 JR MacDougall et al
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enhancement of lung colonization by these cells was statistically
significant (P , 0.05) by a one-sided Mann–Whitney U-test.
DISCUSSION
It is generally accepted that, while not widely expressed in normal
tissues, members of the matrix metalloproteinase family of
enzymes are often overexpressed in a wide variety of advanced
cancers (Stetler-Stevenson et al, 1996). Furthermore, experiments
involving gene transfection and overexpression of either MMPs
(Powell et al, 1993; Bernhard et al, 1994) or their inhibitors
(DeClerck et al, 1992; Khokha et al, 1992) into tumour cell lines or
treatment of tumour-bearing animals with natural or synthetic
MMP inhibitors (DeClerck et al, 1991; Chirivi et al, 1994; Wang et
al, 1994) suggests a role for these molecules in tumour invasion
and metastasis. Certain lines of evidence, however, suggest an
alternative role for MMPs in tumour progression, that is, at the
level of tumour growth (Khokha et al, 1989; Koop et al, 1994;
Witty et al, 1994) and quite possibly at very early stages of benign
tumour development (Wilson et al, 1997). Although the precise
mechanism by which they act is at present under question, it is
possible they may act through the activation and/or release of
bound growth factors or receptors (Fowlkes et al, 1995; Levi et al,
1996; Manes et al, 1997; Suzuki et al, 1997). It is clear that many
MMPs are overexpressed in cancers through the action of onco-
genes and growth factors which represent positive or stimulatory
signals for expression (Mauviel, 1993; Himelstein et al, 1997). As
such, MMPs regulated in this way represent a positive ‘mode’ of
tumour progression, that is, a gain of function is required for
expression. Constitutive production of MMPs has also been linked
to factors that may repress expression as demonstrated by somatic
hybridization experiments (MacDougall et al, 1995). This example
represents a negative or inhibitory ‘mode’ of tumour progression,
in this case loss of function is required. In either circumstance, the
expression of an MMP seems to be the consequence of a genetic
‘switch’ involved in tumour progression.
The pattern of regulation of endogenous MMP inhibitors,
TIMPs, displays a less clear pattern of ‘switching’ in tumour
progression. To date four TIMP family members have been char-
acterized (TIMPs 1–4). It has been widely thought that the TIMPs
are broad-spectrum inhibitors for all MMPs. There is at least one
notable exception, however. Recent observations have indicated
that while TIMP-2 and -3 are able to functionally inhibit MT1-
MMP, TIMP-1 is not (d’Ortho et al, 1998; Will et al, 1996). The
TIMPs are widely expressed in a large number of normal and
neoplastic systems and with respect to some of the TIMP family
members display a strong degree of tissue specific expression. For
example, TIMP-3 is found tightly associated with the extracellular
matrix in many tissues, while the newest member of this family,
TIMP-4, is found expressed in a tissue-specific fashion in the adult
mouse (Leco et al, 1997). This information, taken together,
suggests that the role of metalloproteinases and their inhibitors in
tumour progression is most likely at the level of MMP:TIMP
balance (Liotta and Stetler-Stevenson, 1991). Given their ‘posi-
tive’ role in malignancy it would be predicted that in benign
tumours this balance is toward MMP inhibition while in advanced,
malignant cancers this balance favours proteolysis.
The data presented here suggest that melanoma cells undergo a
‘switch’ with respect to MMP/TIMP induction by cytokines. WM
115 cells, derived from a primary melanoma, were unable to
induce gelatinase B expression in response to TNF-a or IL-1b
treatment while the genetically related cell line, WM 239, derived
from a lymph node metastasis 16 months later, was able to do so in
response to the same cytokine treatment. It could be thought that
the primary cell line was, for some reason, non-responsive to TNF-
a or IL-1b and that sensitivity to the effects of these cytokines was
a trait that the metastatic cells had acquired with progression. This,
however, is not the case since WM 115 cells were able to respond
to cytokine stimulation. Their response, in stark contrast to WM
239 cells, was to up-regulate the production of the metallo-
proteinase inhibitor, TIMP-1. To our knowledge this is the first
demonstration of such a ‘proteolytic switch’; a switch during
tumour progression that not only involves induction of MMP
production but also a loss of MMP inhibitor induction when the
cells were presented with the same stimulus. Treatment of these
cells with the DNA demethylating agent 2-deoxy-5-azacytidine
demonstrated the ability of both cell lines to up-regulate both
gelatinase B and TIMP-1. This latter effect, with respect to gelati-
nase B, has been subsequently linked to the induction of DNA
binding proteins which complex with elements in the gelatinase B
promoter (unpublished observations).
A similar situation to this has been observed with the growth
inhibitory response of melanoma cells to a wide variety of
cytokines, including IL-6 (Lu and Kerbel, 1993), Oncostatin M,
TNF-a (Lu et al, 1993) and TGF-b (MacDougall and Kerbel,
1993). These studies have found that while early-stage melanoma
cells are growth inhibited by these cytokines, advanced-stage
melanoma cells become resistant to the growth inhibitory action of
these factors. However, what sets the present study apart from
these previous studies is the fact that when confronted with the
same stimulus both cell lines responded but in a different manner.
The results presented here demonstrate a reversal of responsive-
ness to cytokine treatment as a function of tumour progression,
from proteolytic inhibition to proteolytic stimulation, and not just
loss of responsiveness.
The mechanism behind this observation is not at all understood.
However, the data presented suggest that the cellular response to
treatment, and not necessarily the treatment itself, is what governs
a given pattern of gene expression. In other words, the pattern of
gene expression by a given cell in response to a stimulus may not
only be determined by that particular stimulus but also by what
genes are permissive for expression under those conditions. In
short, the ability of a cell to respond to a given factor or cytokine is
as important to determination of phenotype as the agent used to
elicit such a response. In the case of WM 115 and WM 239, it is
clear that they are both able to respond to the same cytokine treat-
ment; however, one cell line favours the proteolytic mode (WM
239) by up-regulation of gelatinase B while the other cell line
favours the inhibitory mode (WM 115) by up-regulation of TIMP-
1. This is consistent with our previous observations demonstrating
that the expression of gelatinase B in ‘early’ vs ‘advanced’
melanoma cells can be controlled by a strong repressor as deter-
mined by somatic hybrid studies (MacDougall et al, 1995). This
observation may, in part, explain the inability of ‘early’ melanoma
cells to be induced to express gelatinase B. Further studies aimed
at the regulation of TIMP-1 might elucidate a similar mechanism
at play in this system.
Much of the current literature suggests that MMP expression
in cancers is not associated with the malignant cells but in fact
with stromal elements of a tumour. For example, The MMP
stromelysin-3 is strongly associated of invasive breast cancers, but
its expression is never associated with the tumour cells themselvesGelatinase B and TIMP-1 induction in melanoma progression 511
British Journal of Cancer (1999) 80(3/4), 504–512 © Cancer Research Campaign 1999
(Basset et al, 1990; Chenard et al, 1996). This is true for a number
of MMPs, in a variety of cancers. On the other hand, in chemically
induced murine skin carcinogenesis, the MMP stromelysin-1 in
fact undergoes a ‘switch’ in its localization of expression from
stromal cells within ‘early’ squamous tumours, to being expressed
by the tumour cells themselves in ‘advanced’, metastatic spindle
cell tumours (Wright et al, 1994). In the case of gelatinase B it has
been found that a number of aggressive cancers, when examined
for expression in situ, show tumour cell-associated expression of
this molecule (Pyke et al, 1992; Canete-Soler et al, 1994; Soini
et al, 1994; Rao et al, 1996; Ueda et al, 1996). This information
suggests that gelatinase B in particular might be an important
determinant of aggressive behaviour in many cancers.
The potential role for gelatinase B in metastasis of melanoma is
supported by the fact that when gelatinase B was constitutively
overexpressed in two melanoma cell lines, including WM 239, an
enhancement of lung colonization was observed as was the pres-
ence of extrapulmonary metastases. This is in agreement with other
studies which show that overexpression of gelatinase B results in
an enhancement of lung colonization (Bernhard et al, 1994) or that
down-regulation of gelatinase B expression, through the action of a
gelatinase B-directed ribozyme, results in a decrease in the occur-
rence of experimental lung metastases (Hua and Muschel, 1996;
Sehgal et al, 1998). The exact mechanism by which MMP-9 acts to
enhance metastasis is not well understood, however. Traditionally,
it has been thought that MMPs, in general, enhance the ability of
cells to invade surrounding tissues or to extravasate from the circu-
lation (Stetler-Stevenson et al, 1993). However, recent experi-
mental evidence suggests that MMPs may actually be operating at
the level of tumour growth (Chambers and Matrisian, 1997), and
gelatinase B in particular may be acting to promote angiogenesis
since expression of gelatinase B has been associated with this
process in a number of systems (Canete-Soler et al, 1995; Vu et al,
1998). It is interesting to speculate on the possible in vivo role for
the observed ‘switch’ in cytokine responsiveness in melanoma
progression. It is known, somewhat paradoxically, that a brisk host
inflammatory response leading to regression of the lesion is, in fact,
a poor prognostic factor for the development of metastases in
patients with melanoma (Gromet et al, 1978; Ronan et al, 1987;
Clark et al, 1989). Given the role of TNF-a and IL-1b in such an
inflammatory response it is quite possible that this ‘switch’ in
responsiveness to inflammatory cytokines might represent a molec-
ular basis for the selection of aggressive variants, or the onset of
angiogenesis, during such a host response which, in turn, portends
to an unfavourable disease outcome.
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